{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.3","upperLimit":"89.8","value":"77.6"},{"groupId":"OG001","lowerLimit":"76.7","upperLimit":"96.6","value":"86.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"The percentage of participants surviving one year after starting treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle)","id":"OG000","title":"Phase II: VR-DA-EPOCH"},{"description":"Arm B (DA-R-EPOCH), which is the same treatment as Arm A, but without Vorinostat","id":"OG001","title":"Phase II: DA-R-EPOCH"}],"paramType":"NUMBER","populationDescription":"Eligible randomized participants.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Overall Survival (OS) (Phase II)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}